Denis M. Malvy

Denis M. Malvy

Bordeaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 176 publications

Investigation of barriers and facilitators to implementing a randomised controlled trial during health emergency using the PEARLES framework: insights from the coverage Africa trial on COVID-19 treatments in Burkina Faso.

Investigation of barriers and facilitators to implementing a randomised controlled trial during health emergency using the PEARLES framework: insights from the coverage Africa trial on COVID-19 treatments in Burkina Faso.

Journal: BMJ open

Published: July 06, 2026

Frequency and persistence of post-acute symptoms after chikungunya, dengue, Zika and malaria in travellers: a prospective multi-centre study.

Frequency and persistence of post-acute symptoms after chikungunya, dengue, Zika and malaria in travellers: a prospective multi-centre study.

Journal: Journal of travel medicine

Published: March 28, 2026

Genomic Epidemiology of West Nile Virus in Paris.

Genomic Epidemiology of West Nile Virus in Paris.

Journal: JAMA network open

Published: February 16, 2026

Post-discharge sequelae of Lassa fever survivors in Nigeria: an analysis of the LASCOPE prospective cohort.

Post-discharge sequelae of Lassa fever survivors in Nigeria: an analysis of the LASCOPE prospective cohort.

Journal: The Lancet. Infectious diseases

Published: November 12, 2025

Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial.

Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: July 23, 2025

Self-collected finger-prick blood for gene expression profiling: Unveiling early immune responses in mild COVID-19.

Self-collected finger-prick blood for gene expression profiling: Unveiling early immune responses in mild COVID-19.

Journal: iScience

Published: May 06, 2025

Paradigm Shift Toward "One Health" Monitoring of Culex-Borne Arbovirus Circulation in France: The 2022 Inaugural Spotlight on West Nile and Usutu Viruses in Nouvelle-Aquitaine.

Paradigm Shift Toward "One Health" Monitoring of Culex-Borne Arbovirus Circulation in France: The 2022 Inaugural Spotlight on West Nile and Usutu Viruses in Nouvelle-Aquitaine.

Journal: Open forum infectious diseases

Published: October 22, 2024

Optimizing Health Across Humans, Animals, Plants, and Ecosystems: How Long Before Benefits Turn Harmful-and Harm Becomes Healing?

Optimizing Health Across Humans, Animals, Plants, and Ecosystems: How Long Before Benefits Turn Harmful-and Harm Becomes Healing?

Journal: Open forum infectious diseases

Published: October 08, 2024

Molecular Xenomonitoring (MX) allows real-time surveillance of West Nile and Usutu virus in mosquito populations.

Molecular Xenomonitoring (MX) allows real-time surveillance of West Nile and Usutu virus in mosquito populations.

Journal: PLoS neglected tropical diseases

Published: August 11, 2024

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.

Journal: EBioMedicine

Published: July 17, 2024

Epidemiology of travel-associated dengue from 2007 to 2022: A GeoSentinel analysis.

Epidemiology of travel-associated dengue from 2007 to 2022: A GeoSentinel analysis.

Journal: Journal of travel medicine

Published: May 05, 2024

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial.

Journal: The Journal of infection

Published: February 02, 2024

Showing 1-12 of 176

Last Updated: 09/26/2026